Alzheimer'
Conditions
Interventions
None listed
Sponsors
National Center for Geriatrics and Gerontology
The Tokyo Metropolitan Institute of Gerontology Kindai University Hospital Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Alzheimer's disease (AD) 2) non-AD dementia 3) Mild cognitive impairment (MCI) 4) Healthy volunteer Having no significant disease and good state of the body condition.
Exclusion criteria
Exclusion criteria: Having a risk for the MRI measurements, such as a heart pacemaker, implanted body metals, and a nerve stimulator. Having significant disease. A history of alcohol or drug addiction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of the study is to evaluate the ability of our plasma biomarkers to estimate the presence (or absence) of brain amyloid deposition, by referring the results of amyloid-PET imaging as the gold standard. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) To test quantitative correlation between plasma biomarker values and brain amyloid deposition. 2) To evaluate the performances (e.g. sensitivity and specificity) of the biomarkers for each clinical category 3) Longitudinal changes between the changes in clinical symptoms and biomarker values. | — |
Countries
Japan
Contacts
Public ContactAkinori Nakamura
National Center for Geriatrics and Gerontology Department of Clinical and Experimental Neuroimaging
Outcome results
None listed